WO2010129138A3 - Phosphorylated and phosphonated pyrone analogs for therapeutic treatment - Google Patents
Phosphorylated and phosphonated pyrone analogs for therapeutic treatment Download PDFInfo
- Publication number
- WO2010129138A3 WO2010129138A3 PCT/US2010/030613 US2010030613W WO2010129138A3 WO 2010129138 A3 WO2010129138 A3 WO 2010129138A3 US 2010030613 W US2010030613 W US 2010030613W WO 2010129138 A3 WO2010129138 A3 WO 2010129138A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- derivative
- prevention
- treatment
- phosphonated
- Prior art date
Links
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- -1 for example Substances 0.000 abstract 1
- 230000010030 glucose lowering effect Effects 0.000 abstract 1
- 102000040811 transporter activity Human genes 0.000 abstract 1
- 108091092194 transporter activity Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012507250A JP2012525331A (en) | 2009-04-27 | 2010-04-09 | Phosphorylated pyrone analogs for therapeutic treatment |
EP10714412A EP2424541A2 (en) | 2009-04-27 | 2010-04-09 | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17316909P | 2009-04-27 | 2009-04-27 | |
US61/173,169 | 2009-04-27 | ||
US22518309P | 2009-07-13 | 2009-07-13 | |
US61/225,183 | 2009-07-13 | ||
US24311109P | 2009-09-16 | 2009-09-16 | |
US61/243,111 | 2009-09-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010129138A2 WO2010129138A2 (en) | 2010-11-11 |
WO2010129138A3 true WO2010129138A3 (en) | 2011-12-29 |
Family
ID=42227709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/030613 WO2010129138A2 (en) | 2009-04-27 | 2010-04-09 | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2424541A2 (en) |
JP (1) | JP2012525331A (en) |
WO (1) | WO2010129138A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2473150A (en) * | 2007-07-31 | 2011-03-02 | Limerick Biopharma Inc | Quercetin-3'-O-phosphate |
MX2010001141A (en) | 2007-07-31 | 2010-03-01 | Limerick Biopharma Inc | Phosphorylated pyrone analogs and methods. |
WO2012170430A1 (en) | 2011-06-06 | 2012-12-13 | Cardero Therapeutics, Inc. | Methods and compositions for treatment of mitochondrial toxicity |
US20140088372A1 (en) * | 2012-09-25 | 2014-03-27 | Google Inc. | Information processing method |
CA2887488C (en) * | 2012-10-11 | 2020-07-14 | Armaron Bio Pty Ltd | Novel flavonoid compounds and uses thereof |
CN103641807B (en) * | 2013-12-25 | 2015-12-09 | 南通大学 | A kind of extracting method of apigenin, the pharmaceutical composition being used for the treatment of diabetes and application thereof |
US9260461B2 (en) * | 2014-02-03 | 2016-02-16 | Versitech Limited | Water-soluble derivatives and prodrugs of acacetin and methods of making and using thereof |
CN104530127B (en) * | 2014-12-12 | 2016-09-14 | 广东东阳光药业有限公司 | A kind of two derivatives from icariin and investigation and using method thereof and purposes |
CN104860993B (en) * | 2015-05-22 | 2017-08-22 | 北京盛诺基医药科技有限公司 | A kind of chromocor compound prodrug and application thereof |
CN108465002A (en) * | 2018-06-21 | 2018-08-31 | 黑龙江中医药大学 | A kind of pharmaceutical composition that treating atherosclerosis and its application |
CN109045014B (en) * | 2018-07-02 | 2021-02-26 | 宁夏医科大学 | Application of vitexin in preparing medicine for treating diabetic function and low fertility |
CN108752378A (en) * | 2018-07-12 | 2018-11-06 | 四川福思达生物技术开发有限责任公司 | A kind of synthetic method of methyl hypophosphorous acid monoalkyl ester |
EP3594209A1 (en) * | 2018-07-13 | 2020-01-15 | Centre National De La Recherche Scientifique (Cnrs) | Lipophenolic flavonoid derivatives useful to reduce carbonyl and oxidative stresses (cos) |
KR102349477B1 (en) * | 2019-08-30 | 2022-01-10 | (주)프론트바이오 | Pharmaceutical composition for preventing or treating cancer comprising biguanides, and flavone, hydroxyflavone, flvanone, flavone derivatives, hydroxyflavone derivatives, flavanone derivatives as active ingredients |
CN112481314B (en) * | 2020-12-04 | 2022-09-06 | 江南大学 | Method for preparing inhibitor for inhibiting activities of alpha-amylase and glucosidase |
CN113440514B (en) | 2021-08-20 | 2022-09-09 | 中国农业科学院郑州果树研究所 | Composition containing hesperetin and application thereof in preparation of hypoglycemic drugs |
KR102630951B1 (en) * | 2022-05-18 | 2024-01-29 | 제주대학교 산학협력단 | Composition for anti-inflammation comprising 5-hydroxymaltol |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0666265A1 (en) * | 1993-08-20 | 1995-08-09 | Otsuka Pharmaceutical Factory, Inc. | Phosphonic diester derivative |
WO2003022994A2 (en) * | 2001-09-06 | 2003-03-20 | Synorx, Inc. | Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto |
US20040059136A1 (en) * | 2000-10-06 | 2004-03-25 | Jean-Pierre Gesson | 7-carboxy-flavone derivatives preparation method and therapeutic use |
WO2004037193A2 (en) * | 2002-10-22 | 2004-05-06 | Jenken Biosciences, Inc. | Chromones and chromone derivatives and uses thereof |
DE102006050925A1 (en) * | 2006-10-28 | 2008-04-30 | Merck Patent Gmbh | New ((4-oxo-4H-chromen-3-yl)-hydroxymethyl)- or ((4-oxo-4H-chromen-3-yl)-methyl)-phosphoric acid derivatives are elastase inhibitors useful e.g. to prepare a preparation exhibiting protecting effect against oxidative stress on body cells |
WO2008150085A2 (en) * | 2007-06-07 | 2008-12-11 | Dong-A Pharm. Co., Ltd. | 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same |
WO2009018338A2 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
WO2010134082A1 (en) * | 2009-05-21 | 2010-11-25 | Proteologics Ltd | Chromenone derivatives for treatment of cancer |
-
2010
- 2010-04-09 JP JP2012507250A patent/JP2012525331A/en not_active Withdrawn
- 2010-04-09 EP EP10714412A patent/EP2424541A2/en not_active Withdrawn
- 2010-04-09 WO PCT/US2010/030613 patent/WO2010129138A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0666265A1 (en) * | 1993-08-20 | 1995-08-09 | Otsuka Pharmaceutical Factory, Inc. | Phosphonic diester derivative |
US20040059136A1 (en) * | 2000-10-06 | 2004-03-25 | Jean-Pierre Gesson | 7-carboxy-flavone derivatives preparation method and therapeutic use |
WO2003022994A2 (en) * | 2001-09-06 | 2003-03-20 | Synorx, Inc. | Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto |
WO2004037193A2 (en) * | 2002-10-22 | 2004-05-06 | Jenken Biosciences, Inc. | Chromones and chromone derivatives and uses thereof |
DE102006050925A1 (en) * | 2006-10-28 | 2008-04-30 | Merck Patent Gmbh | New ((4-oxo-4H-chromen-3-yl)-hydroxymethyl)- or ((4-oxo-4H-chromen-3-yl)-methyl)-phosphoric acid derivatives are elastase inhibitors useful e.g. to prepare a preparation exhibiting protecting effect against oxidative stress on body cells |
WO2008150085A2 (en) * | 2007-06-07 | 2008-12-11 | Dong-A Pharm. Co., Ltd. | 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same |
WO2009018338A2 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
WO2010134082A1 (en) * | 2009-05-21 | 2010-11-25 | Proteologics Ltd | Chromenone derivatives for treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
EP2424541A2 (en) | 2012-03-07 |
JP2012525331A (en) | 2012-10-22 |
WO2010129138A2 (en) | 2010-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010129138A3 (en) | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment | |
WO2010042886A3 (en) | Pyrones for the treatment of metabolic disorders | |
PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
MX2013004699A (en) | Pharmaceutical combinations for the treatment of metabolic disorders. | |
PH12015500407A1 (en) | Methods of treating hypertriglyceridemia | |
WO2008070346A3 (en) | Methods for treating pain with reduced nuasea and vomiting | |
BR112013024973A2 (en) | prevention of hypoglycemia in patients with type 2 diabetes mellitus | |
WO2009018326A3 (en) | Soluble pyrone analogs methods and compositions | |
WO2012149157A3 (en) | Heterocyclic compounds for the inhibition of pask | |
WO2012055967A3 (en) | Treating diabetes melitus using insulin injections administered with varying injection intervals | |
EA021275B9 (en) | Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease | |
AR047993A1 (en) | PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES | |
BR112013032265A2 (en) | continuous subcutaneous insulin infusion methods with a hyaluronan degradation enzyme | |
EP2949344A3 (en) | Use of intracellular enzymes for the release of covalently linked bioactives | |
WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
MX2013002725A (en) | Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle. | |
MX2010001141A (en) | Phosphorylated pyrone analogs and methods. | |
PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
WO2012119046A3 (en) | Heterocyclic compounds for the inhibition of pask | |
WO2013109342A8 (en) | Method of treating diabetes using non-glycosylated apolipoprotein a-iv | |
WO2013155528A3 (en) | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels | |
EP2219652A4 (en) | Phospholipid compositions and uses thereof | |
WO2007070355A3 (en) | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes | |
PH12014501646A1 (en) | Substituted phenylazole derivative | |
BRPI0607976A2 (en) | pharmaceutical composition and use of a composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10714412 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012507250 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010714412 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |